Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency
Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis.
Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis
Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization.
PARI Pharma spin-out Breath Therapeutics acquired by Zambon Pharma
